UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~December~~March 2018, ~~2024~~2025

Kronos Bio, Inc.

(Exact name of registrant as specified in its charter)


Delaware	001-39592	82-1895605
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1300 So. El Camino Real, Suite 400

San Mateo, California 94402

(Address of principal executive offices including zip code)

Registrant’s telephone number, including area code: (650) 781-5200

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.001 par value per share

KRON

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 12.02 Results ~~Termination~~ of aOperations ~~Material~~and ~~Definitive~~Financial ~~Agreement.~~Condition

On ~~December~~March 2018, ~~2024~~2025, Kronos Bio, Inc. (the “Company”) ~~entered~~issued ~~into~~ a ~~Transition~~press ~~Agreement~~release ~~and~~announcing ~~Mutual~~its ~~General~~financial ~~Release~~results ~~(the~~for ~~“Transition Agreement”) with Genentech, Inc. and F. Hoffmann-La Roche Ltd (together, “Genentech”), pursuant to which~~ the ~~Company~~fourth ~~and~~quarter ~~Genentech agreed to void~~ and ~~cancel~~year ~~all~~ended ~~of the parties’ respective rights and obligations under the Collaboration and License Agreement between the parties dated January 6~~December 31, ~~2023 (the “Collaboration Agreement”)~~2024. ~~Pursuant~~A tocopy the Transition Agreement, the Company will transfer and assign to Genentech all small molecule compounds, materials, data, and intellectual property generated by the Company in connection with the two discovery research programs (“Program Materials”) conducted by the Company under the Collaboration Agreement, but excluding the Company’s proprietary drug discovery platform. The Company also granted to Genentech a perpetual, irrevocable, non-exclusive and fully paid up license under certain related intellectual property owned or controlled by the Company that is necessary or reasonably useful to exploit the Program Materials. The Transition Agreement has the effect of ~~terminating~~ the ~~Collaboration~~press ~~Agreement, and provides for a general~~ release ofis ~~any~~being ~~actual~~furnished oras ~~potential~~Exhibit ~~claims between the Company and Genentech relating thereto~~99.1 ~~In addition, the Transition Agreement cancels and voids any and all downstream payment obligations between the parties relating~~ to orthis ~~arising~~Report ~~from~~on ~~the~~Form ~~Collaboration Agreement or any programs or compounds arising thereunder. The Company has made a one~~8-~~time payment in connection with the termination of the Collaboration Agreement, which is intended to support the transition of all activities under the Collaboration Agreement to Genentech~~K.

The ~~foregoing~~information isin athis ~~summary~~Report ~~description~~on ofForm ~~certain~~8-K ~~terms~~and ofExhibit ~~the~~99.1 ~~Transition~~attached ~~Agreement~~hereto ~~and~~is ~~does~~intended ~~not purport~~ to be ~~complete,~~furnished and isshall ~~qualified~~not inbe ~~its~~deemed ~~entirety~~“filed” byfor ~~reference~~purposes toof Section 18 of the ~~full~~Securities ~~text~~Exchange Act of 1934 (the ~~Transition~~“Exchange ~~Agreement~~Act”) or otherwise subject to bethe ~~filed~~liabilities of that section, ~~with~~nor ~~confidential~~shall ~~terms~~it ~~redacted,~~be asdeemed anincorporated ~~exhibit~~by toreference in any filing under the ~~Company’s~~Securities ~~Annual~~Act ~~Report~~of on1933, ~~Form~~as ~~10-K~~amended, ~~for~~or the ~~year~~Exchange ~~ending~~Act, ~~December~~except ~~31,~~as ~~2024~~expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No.						Description


99.1						Press Release, dated March 18, 2025.
104						The cover page of this report has been formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

KRONOS BIO, INC.

Dated: December 27, 2024

By:

/s/ Deborah Knobelman

Dated: March 18, 2025

By:

/s/ Deborah Knobelman

Deborah Knobelman, Ph.D.

President, Interim Chief Executive Officer, Chief Financial Officer and Chief Operating Officer

Filing Compare · Kronos Bio, Inc.